Ken Griffin Ionis Pharmaceuticals Inc Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$40.06 - $51.86 $3.54 Million - $4.58 Million	-88,300 Reduced 60.81%	56,900 $2.28 Million
Q2 2024 Aug 14, 2024	BUY	$36.45 - $47.7 $269,730 - $352,980	7,400 Added 5.37%	145,200 $6.92 Million
Q1 2024 May 15, 2024	BUY	$42.03 - $53.55 $3.84 Million - $4.89 Million	91,400 Added 196.98%	137,800 $5.97 Million
Q4 2023 Feb 14, 2024	BUY	$43.39 - $51.63 $525,019 - $624,723	12,100 Added 35.28%	46,400 $2.35 Million
Q3 2023 Nov 14, 2023	SELL	$38.5 - $47.13 $642,950 - $787,071	-16,700 Reduced 32.75%	34,300 $1.56 Million
Q2 2023 Aug 14, 2023	BUY	$34.73 - $43.33 $1.52 Million - $1.89 Million	43,700 Added 598.63%	51,000 $2.09 Million
Q1 2023 May 15, 2023	SELL	$33.58 - $41.2 $940,240 - $1.15 Million	-28,000 Reduced 79.32%	7,300 $260,000
Q4 2022 Feb 14, 2023	SELL	$37.12 - $46.52 $556,800 - $697,800	-15,000 Reduced 29.82%	35,300 $1.33 Million
Q3 2022 Nov 14, 2022	SELL	$36.54 - $48.66 $40,194 - $53,525	-1,100 Reduced 2.14%	50,300 $2.23 Million

402

136M

862K

582K

Ticker IONS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,940,992
Market Cap $5.06B
Description
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for famil...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.